Mohawk Industries vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Calhoun GA world's largest flooring company (NYSE: MHK) at $10.8B 2024 revenue (-2.7%); $285M restructuring savings by 2026 and $520M 2025 capex with Pergo/Daltile/Quick-Step brands competing with Shaw for residential flooring.
About
Mohawk Industries, Inc. is a Calhoun, Georgia-based global flooring manufacturer — publicly traded on the New York Stock Exchange (NYSE: MHK) as an S&P 500 and Fortune 500 component — operating as the world's largest flooring company with 43,000 employees, manufacturing facilities in 15 countries, and a brand portfolio spanning carpet, ceramic tile, laminate, luxury vinyl tile (LVT), hardwood, and stone surfaces. In fiscal year 2024, Mohawk reported net sales of $10.8 billion (down 2.7% year-over-year) and net earnings of $518 million ($8.14 EPS). Mohawk's brand portfolio includes Pergo (laminate), Quick-Step (LVT and laminate), Daltile and American Olean (ceramic tile), Karastan (premium carpet), Unilin (panels and flooring), and Moduleo (LVT). The company announced plans to invest approximately $520 million in 2025 for capacity expansion and operational improvements while implementing restructuring to achieve $285 million in annual savings by 2026. Mohawk traces its roots to 1875 when the Shuttleworth family established a carpet mill in the Hudson Valley; the modern company was spun off from Mohasco Corporation in 1988 and went public in 1992.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.